middle.news
Starpharma Raises $32 Million to Advance DEP® HER2-Lutetium Trial
9:03am on Wednesday 15th of July, 2026 AEST
•
Pharmaceuticals, Biotechnology & Life Sciences
Read Story
Starpharma Raises $32 Million to Advance DEP® HER2-Lutetium Trial
9:03am on Wednesday 15th of July, 2026 AEST
Key Points
Fully underwritten $32 million entitlement offer at $0.57 per share
Funds to complete DEP® HER2-Lu Phase 1 trial and expand oncology pipeline
DEP® HER2-Lu preclinical data supports strong tumour targeting and retention
New patent filed for DEP® radioligand therapy platform
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE